Senior Health Home > What Is Risedronate Delayed-Release Used For?
Healthcare providers may recommend the use of risedronate delayed-release for postmenopausal women with osteoporosis. The medication works by slowing down the rate at which bone breaks down, which can lead to improved bone mass. Although risedronate delayed-release is not approved for premenopausal women, it may be used off-label in this group to treat osteoporosis and certain other conditions.
An Introduction to Uses of Risedronate Delayed-ReleaseRisedronate delayed-release (Atelvia™) is a prescription medication that is part of a group of drugs known as bisphosphonates. It is approved for the treatment of osteoporosis in postmenopausal women.
Osteoporosis, which means "porous bone," is a disease characterized by low bone mass (bone thinning) that leads to fragile bones and to an increased risk of fractures of the hip, spine, and wrist. Men as well as women are affected by this condition. Fortunately, osteoporosis is a disease that can be prevented and treated.
Common causes of osteoporosis include:
- Age-related bone loss
- Alcohol abuse
- Long-term corticosteroid use
- Certain diseases.
It is also thought that race and ethnicity may play a role in developing osteoporosis, but more research is needed to determine the connection.
Often, osteoporosis treatment is not started until a bone is broken, as there are usually no symptoms. However, treatment may be started earlier if the disease is detected using a test (see Diagnosing Osteoporosis). In fact, some osteoporosis medications (but not risedronate delayed-release) are approved to prevent the condition in people who are at high risk for developing it (see Risk Factors for Osteoporosis).